Medical complications of new antipsychotic drugs

Schizophrenia Bulletin

Volumn 22, Issue 3, 1996, Pages 475-483

  Umbricht, Daniel ^a,b   Kane, John M ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; AKATHISIA; HUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0029821861     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/22.3.475     Document Type: Review

References (70)

1. Addington, D.E.; Toews, J.; and Addington, J.M. Risperidone and tardive dyskinesia: Case report. Journal of Clinical Psychiatry, 56:484-485, 1995.
2. Alvir, J.M.J.; Lieberman, J.A.; Safferman, A.Z.; Schwimmer, J.L.; and Schaaf, J.A. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine, 329(3):162-167, 1993.
3. American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: The Association, 1992.
4. Anderson, E.S., and Powers, P.S. Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry, 52:102-104, 1991.
5. Berman, I.; Zalma, A.; Durand, C.J.; and Green, A.I. Clozapine-induced myoclonic jerks and drop attacks. [Letter] Journal of Clinical Psychiatry, 53(9):329-330, 1992.
6. Bernstein, J.L. Induction of obesity by psychotropic drugs. Academic Science, 499:203-215, 1987.
7. Borison, R.L.; Diamond, B.I.; Sinha, D.; Gupta, R.P.; and Ajiboye, P.A. Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin, 24(2):260-263, 1988.
8. Brady, K.T. Weight gain associated with psychotropic drugs. Southern Medical Journal, 82:611-616, 1989.
9. Breier, A.; Buchanan, R.W.; Kirkpatrick, B.; Davis, O.R.; Irish, D.; Summerfelt, A.; and Carpenter, W.T., Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151(1):20-26, 1994.
10. Casey, D.E. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 99(Suppl.):47-55, 1989.
11. Ceskova, E., and Svestka, J. Double-blind comparison of risperidone and haloperidol in schizophrenia and schizoaffective psychoses. Pharmacopsychiatry, 26:121-124, 1993.
12. Chengappa, K.N.; Shelton, M.D.; Baker, R.W.; Schooler, N.R.; Baird, J.; and Delaney, J. The prevalence of akathisia in patients receiving stable doses of clozapine. Journal of Clinical Psychiatry, 55(4):142-145, 1994.
13. Chouinard, G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter study. Journal of Clinical Psychopharmacology, 15(Suppl. 1):36-44, 1995.
14. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D..; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; and Arnott, W. A Canadian placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993.
15. Claghorn, J.; Honigfeld, G.; and Abuzzahab, F.S. The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7:377-384, 1987.
16. Claus, A.; Bollen, J.; de Cuyper, H.; Eneman, M.; Malfroid, M.; Peuskens, J.; and Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 83:295-305, 1992.
17. Clozapine Study Group. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the U.K. British Journal of Psychiatry, 163:150-154, 1993.
18. Cohen, B.M.; Keck, P.E.; Satlin, A.; and Cole, J.O. Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry, 29:1215-1219, 1991.
19. Das Gupta, K., and Young, A. Induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 52:105-107, 1991.
20. Dave, M. Clozapine-related tardive dyskinesia. Biological Psychiatry, 35:886-887, 1994.
21. de Leon, J.; Stanilla, J.K.; White, A.O.; and Simpson, G.M. Anticholinergics to treat clozapine withdrawal. Journal of Clinical Psychiatry, 55:119-120, 1994.
22. Dev, V.J., and Krupp, P. Adverse event profile and safety of clozapine. Reviews in Contemporary Pharmacotherapy, 6:197-208, 1995.
23. Dev, V.J.; Rosenberg, T.; and Krupp, P. Agranulocytosis in clozapine. [Letter] British Medical Journal 309:54, 1994.
24. Devinsky, O.; Honigfeld, G.; and Patten, J. Clozapine-related seizures. Neurology, 41:369-371, 1991.
25. Devinsky, O., and Pacia, S.V. Seizures during clozapine therapy. Journal of Clinical Psychiatry, 55(Suppl. B):153-156, 1994.
26. Doss, F.W. The effect of antipsychotic drugs on body weight: A retrospective review. Journal of Clinical Psychiatry, 40:528-530, 1979.
27. Geibig, C.B., and Marks, L.W. Treatment of clozapine- and molindone-induced agranulocytosis with granulocyte colony-stimulating factor. Pharmacotherapy, 27:1190-1192, 1993.
28. Gerlach, J.; Jorgensen, E.O.; and Peacock, L. Long-term experience with clozapine in Denmark: Research and clinical practice. Psychopharmacology, 99(Suppl.):92-96, 1989.
29. Gerlach, J., and Peacock, L. Motor and mental side effects of clozapine. Journal of Clinical Psychiatry, 55(Suppl. B):107-109, 1994.
30. Harmon, L.; Berisford, A.; Ames, D.; Wirshing, W.C.; and Marder, S.R. Weight gain associated with effects of atypical antipsychotics. [Abstract] Neuropsychopharmacology, 10(Suppl.):139, 1994.
31. Honigfeld, G., and Patin, J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry, 41:882-885, 1990.
32. Hoyberg, O.J.; Fensbo, C.; Remvig, J.; Lingjaerde, O.; Sloth-Nielson M.; and Salvensen, I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica, 88:395-402, 1993.
33. Hummer, M.; Kemmler, G.; Kurz, M.; Kurzthaler, I.; Oberbauer, H.; and Fleischhacker, W.W. Weight gain induced by clozapine. European Neuropsychopharmacology, 5:269-271, 1995.
34. Jalenques, I., and Coudert, A.J. Clozapine: A new therapeutic approach in treatment-resistant schizophrenic patients: Long-term prospective study of 16 patients. Acta Psychiatrica Belgica, 92(6):323-338, 1992.
35. Kane, J.; Honigfeld, G.; Singer, J.; and Meltzer, H. Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45:789-796, 1988.
36. Kane, J.; Woerner, M.G.; Pollack, S.; Safferman, A.Z.; and Lieberman, J.A. Does clozapine cause tardive dyskinesia? Journal of Clinical Psychiatry, 54(9):327-330, 1993.
37. Kastrup, O.; Gastpar, M.; and Schwartz, M. Acute dystonia due to clozapine. [Letter] Journal of Neurology, Neurosurgery and Psychiatry, 57:119, 1994.
38. Kurz, M.; Hummer, M.; Oberbauer, H.; and Fleischhacker, W.W. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology, 118:52-56, 1995.
39. Lamberti, J.S., and Bellnier, T. Clozapine and tardive dyskinesia. Journal of Nervous and Mental Disease, 181:137-138, 1993.
40. Lamberti, J.S.; Bellnier, T.; and Schwarzkopf, S.B. Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry, 149:689-690, 1992.
41. Leadbetter, R.; Shutty, M.; and Pavalonis, D. Clozapine-induced weight gain: Prevalence and clinical relevance. American Journal of Psychiatry, 149:68-72, 1992.
42. Leppig, M.; Bosch, B.; Naber, D.; and Hippius, H. Clozapine in the treatment of 121 outpatients. Psychopharmacology, 99:577-579, 1989.
43. Lieberman, J. A.; Kane, J.M.; and Johns, C.A. Clozapine guidelines for clinical management. Review. Journal of Clinical Psychiatry, 50(9):329-338, 1989.
44. Lieberman, J.A.; Safferman, A.Z.; and Pollack, S. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. American Journal of Psychiatry, 151:1744-1752, 1994.
45. Lieberman, J.A.; Saltz, B.L.; Johns, C.A.; Pollack, S.; Borenstein, M.; and Kane, J.M. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158:503-510, 1991.
46. Malow, B.A.; Reese, K.B.; Sato, S.; Bogard, P.J.; Malhotra, A.K.; Su, T.; and Pickar, S.T. Clozapine, myoclonus, and EEG abnormalities. Epilepsia, 34(Suppl. 6):129, 1993.
47. Marder, S.R., and Meibach, R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
48. Miller, C.H.; Umbricht, D.S.G.; Lieberman, J.A.; Mohr, F.; and Fleischhacker, W.W. "The Prevalence and Severity of Acute Extrapyramidal Side Effects in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics." [Abstract] Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 1996.
49. Miller, D.D.; Sharafuddin, M.J.; and Kathol, R.G. A case of clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 52:99-101, 1991.
50. Min, S.K.; Rhee, C.S.; Kim, C.; and Kang, D. Y. Risperidone versus haloperidol in the treatment of chronic schizophrenia patients: A parallel group double-blind comparative trial. Yonsei Medical Journal, 34(2):179-196, 1993.
51. Müller, T.; Becker, T.; and Fritze, J. Neurolepic malignant syndrome after clozapine plus carbamazepine. Lancet, 1:1499-1500, 1988.
52. Musser, W.S.; Wills, C.D.; and Nimgaonkar, V.L. Is there a rapid relapse after discontinuation of clozapine? [Abstract] Biological Psychiatry, 35:742, 1994.
53. Naber, D., and Hippius, H. The European experience with use of clozapine. Hospital and Community Psychiatry, 41:886-890, 1990.
54. Naber, D.; Leppig, M.; Grohmann, R.; and Hippius, H. Efficacy and adverse effects in the treatment of schizophrenia and tardive dyskinesia-A retrospective study of 387 patients. Psychopharmacology, 99(Suppl.):573-576, 1989.
55. Nopoulos, P.; Flaum, M.; and Miller, D.D. Atypical neuroleptic malignant syndrome with atypical neuroleptic clozapine-induced NMS without rigidity. Annals of Clinical Psychiatry, 2:251-253, 1990.
56. Oren, R.; Granat, E., Shtrussberg, S.; and Matzner, Y. Clozapine-induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. British Journal of Psychiatry, 162:686-687, 1993.
57. Palia, S.S., and Clarke, E.J. Clozapine withdrawal syndrome. Psychiatry Bulletin, 17:374-375, 1993.
58. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166(6):712-733, 1995.
59. Pope, H.; Cole, J.O.; Choras, P.; and Fulwiler, C. Apparent neuroleptic malignant syndrome with clozapine and lithium. Journal of Nervous and Mental Disease, 174:493-495, 1986.
60. Povlsen, J.J.; Noring, U.; Fog, R.; and Gerlach, J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatrica Scandinavica, 71:176-185, 1985.
61. Raitasuo, V.; Vataja, R.; and Elomaa, E. Risperidone-induced neuroleptic malignant syndrome in young patient. [Letter] Lancet, 344:1705, 1994.
62. Reddig, A.; Minnema, A.M.; and Tandon, R. Neuroleptic malignant syndrome and clozapine. Annals of Clinical Psychiatry, 5:25-27, 1992.
63. Safferman, A.Z.; Lieberman, J.A.; Pollack, S.; and Kane, J.M. Akathisia and clozapine treatment. Schizophrenia Research, 9:248-249, 1993.
64. Schmauss, M.; Wolff, R.; Erfurth, A.; and Ruther, E. Tolerability of long-term clozapine treatment. Psychopharmacology, 99(Suppl.):105-108, 1989.
65. Tamminga, C.A.; Thaker, G.K.; Moran, M.; Kakigi, T.; and Gao, X.M. Clozapine in tardive dyskinesia: Observation from human and animal model studies. Journal of Clinical Psychiatry, 55(Suppl. B): 102-106, 1994.
66. Tuan-Ping, S.; Hsiao, J.; Malhotra, A.K.; Litman, R.E.; Hong, W.W.; and Pickar, D. "Weight Gain Associated With Clozapine Treatment of Schizophrenia." Presented at the 146th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May, 1993. p. 127.
67. Umbricht, D.S.G.; Pollack, S.; and Kane, J.M. Clozapine and weight gain. Journal of Clinical Psychiatry, 55(Suppl. B):157-160, 1994.
68. Van Putten, T.; Wirshing, W.C.; and Marder, S.R. Tardive Meige syndrome responsive to clozapine. [Letter] Journal of Clinical Psychopharmacology, 10:381-382, 1990.
69. Webster, P., and Wijeratne, C. Risperidone-induced neuroleptic malignant syndrome. [Letter] Lancet, 344:1228-1229, 1994.
70. Woerner, M.G.; Lieberman, J.A.; Kane, J.M.; and Breitman, B. Risperidone induced tardive dyskinesia?: A case report. American Journal of Psychiatry, in press.